PEG-MGF is a PEGylated form of Mechano Growth Factor with an extended half-life, and the community runs it for muscle growth and repair. Reported doses span 50 µg to 3 mg, most commonly 3 mg, with most users dosing weekly rather than daily. It has no FDA-approved indication, so all human use is off-label or compounded, and the community reporting base is small enough that its track record should be read with caution.
Data last updated
Measured on 3 of 6 axes
Evidence shape
PEG-MGF currently lacks any published human clinical evidence, placing it in the category of peptides with no established research record. There are zero registered trials, no mapped indications, and no completed studies to verify its safety or efficacy in human subjects. Because the existing literature is entirely absent, there is no data to support its use for any therapeutic purpose.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How PEG-MGF is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Based on a single source, clinicians typically administer 200 mcg of PEG‑MGF subcutaneously each day, and no specific cycling regimen is reported.
Based on two anecdotal reports, the dose is 400 mcg of PEG‑MGF given subcutaneously. No specific frequency or cycling regimen was described in these reports.